Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 8/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.68 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9503680 | 1.00 | CYP1B1 (1.00) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1322029 | 0.90 | CYP1A1 (0.82) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1322027 | 0.90 | CYP1A1 (0.82) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7368933 | 0.90 | CYP1B1 (0.83) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20570877 | 0.90 | CYP1A1 (0.82) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL979409 | 0.90 | CYP1B1 (0.83) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31436361 | 0.87 | CYP1A1 (0.77) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31436369 | 0.87 | CYP1A1 (0.77) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1604142 | 0.87 | CYP1A1 (0.77) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| Chalcone SCHEMBL10782584 | 0.86 | CYP1B1 (0.79) | CYP1B1CYP1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4973624-A | Coating resin composition | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1990-11-27 | — | — | US | claimed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| EP-0570992-A1 | Powder coatings | NIPPON PAINT CO., LTD. (JP) | 1993-11-24 | — | — | EP | disclosed |
| EP-0291673-B1 | TETRAHYDROPYRIDINE OXIMES, A PROCESS FOR THEIR PREPARATION AND USE THEREOF AS CHOLINERGIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
| US-5073561-A | N-substituted-pyridinyl oximes | WARNER-LAMBERT COMPANY (US) | 1991-12-17 | — | — | US | disclosed |
| US-5034432-A | Thermosetting or thermoplastic resins for powder coatings | NIPPON PAINT CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0389080-A1 | Powder coatings | NIPPON PAINT CO., LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4929734-A | ANTIINFLAMMATORY AGENTS, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1990-05-29 | — | — | US | disclosed |
| US-4904562-A | DISSOLVED ADDITION COPOLYMER SHELL IS PRECIPITATED ONTO DISPERSED CORE PARTICLES BY VARIATIONS IN PH | CANON KABUSHIKI KAISHA (JP) | 1990-02-27 | — | — | US | disclosed |
| US-4798841-A | COGNITION ACTIVATORS, ANALGESICS | WARNER-LAMBERT COMPANY (US) | 1989-01-17 | — | — | US | disclosed |
| EP-0261686-A1 | Process for producing encapsulated toner | CANON KABUSHIKI KAISHA (JP) | 1988-03-30 | — | — | EP | disclosed |
| US-4710508-A | ANALGESICS | WARNER-LAMBERT COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP1B1 780/4885CYP1A1 656/4885CYP1A2 795/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP1B1 747/4885CYP1A1 649/4885CYP1A2 792/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP1B1 604/4885CYP1A1 625/4885CYP1A2 655/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | CYP1B1 604/4885CYP1A1 625/4885CYP1A2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.